Retatrutide is an investigational triple agonist medication generating significant interest for the treatment of obesity and type 2 diabetes. As a novel drug acting on GLP-1, GIP, and glucagon receptors simultaneously, it represents a step beyond existing approved therapies such as semaglutide and tirzepatide. However, a key question many people are asking is: can anyone take retatrutide? The short answer is no — retatrutide is not yet approved in the UK or elsewhere, access is currently limited to clinical trials, and not everyone would be a suitable candidate even if it were approved. This article explains what is currently known.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from approved agents like semaglutide and tirzepatide, though it has not yet received regulatory approval.

Retatrutide is an investigational medication currently being studied for the treatment of obesity and type 2 diabetes. It belongs to a novel class of drugs known as triple agonists, meaning it simultaneously activates three hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple mechanism of action distinguishes retatrutide from existing approved treatments such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP/GLP-1 agonist).

By activating the GLP-1 receptor, retatrutide is thought to stimulate insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite — effects consistent with the broader GLP-1 receptor agonist class. GIP receptor activation may further enhance insulin response and contribute to effects on fat metabolism. The addition of glucagon receptor agonism has, in early-phase studies, been associated with increased energy expenditure and potential effects on fat stored in the liver; however, these findings are based on preclinical and early human data and should be regarded as investigational signals rather than established benefits. Whether retatrutide will offer meaningful advantages for people with metabolic dysfunction-associated steatotic liver disease (MASLD) remains to be confirmed in Phase 3 trials.

Early-phase clinical trial data, including results from a Phase 2 trial published in 2023 in the New England Journal of Medicine (Jastreboff et al., NEJM 2023), demonstrated substantial weight reduction in participants receiving retatrutide — with some individuals losing more than 20% of their body weight over 48 weeks. These findings have generated considerable scientific interest, though it is important to note that retatrutide remains under investigation and has not yet received regulatory approval for routine clinical use.

Who May Be Suitable for Retatrutide Treatment?

Retatrutide trials have focused on adults with a BMI of 30 kg/m² or above, but many groups — including pregnant individuals, those with pancreatitis history, and under-18s — are excluded, making individual clinical assessment essential.

Because retatrutide has not yet been approved for general use, it is not currently possible to definitively state who will or will not be eligible for this treatment in a clinical setting. However, based on the populations studied in clinical trials to date, researchers have focused primarily on adults living with obesity — typically defined as a body mass index (BMI) of 30 kg/m² or above — as well as those with overweight accompanied by at least one weight-related health condition, such as type 2 diabetes, hypertension, or dyslipidaemia. It is worth noting that in the UK, overweight is defined as a BMI of 25 kg/m² or above; the threshold of 27 kg/m² used in many anti-obesity trials reflects a pharmacotherapy eligibility criterion rather than the standard UK BMI classification.

It is important to understand that not everyone will be a suitable candidate, even if retatrutide eventually receives regulatory approval. Certain groups have been excluded from trials or may face additional risks, including:

• People who are pregnant or breastfeeding, as the safety profile in these groups has not been established

• Individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) — this exclusion reflects trial protocols and the US prescribing label for some GLP-1 receptor agonists; a direct causal link in humans has not been established, and current EU and UK summaries of product characteristics (SmPCs) for approved GLP-1-based therapies do not list this as a formal contraindication, though it remains a theoretical concern warranting caution

• People with severe gastrointestinal conditions, such as gastroparesis or inflammatory bowel disease

• Those with a history of pancreatitis, which has been associated with GLP-1 receptor agonist use

• Children and young people under 18, who have not been studied in retatrutide trials to date

• People with a history of gallbladder disease or gallstones, given the known association between this drug class and gallbladder events

• Those with proliferative diabetic retinopathy or macular oedema, where rapid improvements in blood glucose control may carry additional risks

• People with severe renal or hepatic impairment, pending further safety data

Age-related eligibility, renal function, hepatic status, and existing medications would all need to be carefully assessed by a qualified clinician before any treatment decision could be made. The short answer to whether anyone can take retatrutide is: no — individual medical assessment will be essential.

Current Availability and Regulatory Status in the UK

Retatrutide is not approved by the MHRA or EMA and cannot be legally prescribed in the UK; access is currently only possible through approved clinical trials, with no early access pathway established.

As of the time of writing, retatrutide is not approved for use in the United Kingdom. It has not received a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA), nor has it been granted approval by the European Medicines Agency (EMA). This means it cannot be legally prescribed or dispensed through NHS or private healthcare channels as a licensed medicine. There is currently no MHRA Early Access to Medicines Scheme (EAMS) designation for retatrutide, meaning no pre-approval access pathway has been established.

Retatrutide is currently being evaluated in Phase 3 clinical trials, which are the large-scale studies required to confirm efficacy and safety before a regulatory submission can be made. The manufacturer, Eli Lilly and Company, has initiated these trials across multiple countries, and results are anticipated over the coming years. Until these trials are completed and a regulatory dossier is submitted and reviewed, retatrutide will remain an investigational compound.

Whilst the MHRA does permit access to unlicensed medicines in limited circumstances — for example, through the Specials framework or on a named-patient basis — these routes apply to medicines that are not licensed in the UK but are manufactured or available elsewhere. They are not applicable to retatrutide, which is an investigational product that has not completed the regulatory process in any jurisdiction. Outside of a clinical trial, there is currently no lawful or practical route to access retatrutide in the UK. Patients should be aware that any source offering retatrutide outside of an approved clinical trial setting is operating outside the law and poses serious and unpredictable health risks.

Patients who are interested in participating in clinical trials involving retatrutide may wish to speak with their GP or specialist, who can advise on whether any relevant trials are recruiting in the UK. The NIHR's 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk) provides information on ongoing clinical research opportunities for patients.

Possible Side Effects and Safety Considerations

The most common side effects reported in Phase 2 trials are gastrointestinal, including nausea, vomiting, and diarrhoea; additional risks include pancreatitis, gallbladder disease, and glycaemic disturbances requiring clinical monitoring.

As with all medicines — particularly those acting on multiple hormonal pathways — retatrutide carries a range of potential side effects. Data from Phase 2 trials (Jastreboff et al., NEJM 2023) provide the most detailed safety information currently available, though it is important to recognise that longer-term safety data from Phase 3 trials are still being gathered.

The most commonly reported side effects in trials to date have been gastrointestinal in nature, consistent with the GLP-1 receptor agonist class. These include:

• Nausea — particularly during dose escalation

• Vomiting

• Diarrhoea

• Constipation

• Decreased appetite

These effects were generally mild to moderate in severity and tended to diminish over time as the body adjusted to the medication. However, they led to treatment discontinuation in a proportion of trial participants.

Additional safety considerations relevant to this drug class include:

• Pancreatitis: A theoretical risk based on experience with other GLP-1-based therapies. Seek urgent medical attention if you develop severe, persistent abdominal pain — particularly pain that radiates to the back — with or without vomiting, as these may be symptoms of pancreatitis.

• Gallbladder disease: Cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) have been reported with GLP-1 receptor agonist use. Seek medical advice promptly if you experience severe or persistent pain in the upper right abdomen, fever, or yellowing of the skin or eyes (jaundice).

• Dehydration and acute kidney injury: Prolonged vomiting or diarrhoea can lead to dehydration, which may in turn affect kidney function. Maintain adequate fluid intake and seek medical advice if you are unable to keep fluids down.

• Thyroid C-cell effects: Observed in animal studies with this drug class; a direct causal link in humans has not been established, but remains under investigation.

• Blood glucose management: Retatrutide's glucagon receptor activity introduces additional considerations around glycaemic control, particularly in individuals taking insulin or sulphonylureas, where hypoglycaemia could be a concern.

• Diabetic retinopathy: Rapid improvements in blood glucose control have been associated with worsening of diabetic retinopathy in some patients. People with pre-existing retinopathy should inform their clinician and report any new or worsening visual symptoms promptly.

• Heart rate: Increases in resting heart rate have been observed with incretin-based therapies. Report any symptomatic palpitations or sustained increases in heart rate to your clinician.

Cardiovascular outcomes data are still being collected as part of ongoing trials. Until comprehensive Phase 3 safety data are available and reviewed by regulators such as the MHRA, the full safety profile of retatrutide in diverse patient populations remains incompletely characterised.

Patients and healthcare professionals should report any suspected adverse reactions to medicines — including those received as part of a clinical trial — via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. Patients should not attempt to obtain retatrutide through unregulated online sources, as this poses significant and unpredictable health risks.

Speaking to Your GP or Specialist About Retatrutide

Retatrutide cannot currently be prescribed in the UK outside a clinical trial, but your GP or specialist can assess eligibility for NICE-approved alternatives such as semaglutide or tirzepatide and advise on relevant trial opportunities.

If you have read about retatrutide and are wondering whether it might be appropriate for you, the most important first step is to have an open and informed conversation with your GP or a specialist in obesity medicine or endocrinology. Retatrutide cannot currently be prescribed in the UK outside of a clinical trial, but your clinician can help you understand the current landscape and explore what options are available to you now.

For individuals living with obesity or type 2 diabetes, there are already several NICE-approved treatments that may be suitable. NICE technology appraisal TA875 supports the use of semaglutide (Wegovy®) for weight management within specialist weight management services and defined eligibility criteria. Semaglutide (Ozempic®) is also used in the management of type 2 diabetes in line with NICE guideline NG28. Tirzepatide (Mounjaro®) has received a NICE technology appraisal for use in type 2 diabetes; a separate appraisal for its use in weight management is subject to ongoing NICE guidance processes. Your GP or specialist can assess whether you meet the criteria for these existing therapies, which have established safety and efficacy profiles and are available through NHS or private channels.

You should speak to your GP or seek medical advice if:

• You are considering purchasing weight-loss injections from unregulated online sources

• You have a BMI of 30 kg/m² or above and are struggling to manage your weight through lifestyle measures alone

• You have type 2 diabetes and your current treatment is not achieving adequate blood glucose control

• You are interested in finding out whether any clinical trials involving retatrutide or similar agents are recruiting near you

Your clinician can also help you access structured weight management programmes through the NHS, which remain a cornerstone of evidence-based obesity care. The NIHR 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk) is a useful resource for finding UK clinical trials. Staying informed through reputable sources — such as the NHS website (nhs.uk), NICE (nice.org.uk), and the MHRA (gov.uk/mhra) — will help you make safe and well-considered decisions about your health as new treatments continue to emerge.

Frequently Asked Questions